Biogen stock closes 0.55 percent higher as Q2 growth holds
📈 Biogen stock closed at USD 227.60 on September 25, 2026, up 0.55 percent with a market cap of USD 33.6 billion.
💰 Q2 revenue reached USD 2.74 billion, beating expectations of USD 2.46 billion and growing 3.40% year over year.
📊 Adjusted EPS hit USD 3.60, significantly exceeding the USD 2.94 consensus estimate by USD 0.66.
🎯 Analysts maintain a Moderate Buy rating with an average 12-month price target of USD 230.14.
🔬 Management expects five registrational study readouts across SLE, CLE, AMR, and Dravet syndrome in the next several quarters.
📅 Biogen will report Q3 2026 financial results before the market opens on October 28, 2026.
📉 The stock is currently trading 0.69 percent below its 52-week high of USD 229.19.
Bullish Signals
- Biogen reported Q2 revenue of USD 2.74 billion, a 3.40% year-over-year increase that significantly beat analyst expectations of USD 2.46 billion.
- The company delivered an adjusted EPS of USD 3.60, surpassing the consensus estimate of USD 2.94 by USD 0.66, indicating strong profitability.
- Analysts maintain a Moderate Buy consensus with an average 12-month price target of USD 230.14, suggesting potential upside from current levels.
- Management has outlined five upcoming registrational study readouts across key therapeutic areas including SLE, CLE, AMR, and Dravet syndrome.
Full Analysis
Biogen Inc. shares closed at USD 227.60 on September 25, 2026, marking a 0.55 percent gain as the company reported robust second-quarter financial results. The biotechnology firm posted Q2 revenue of USD 2.74 billion, representing a 3.40 percent year-over-year increase that significantly exceeded analyst expectations of USD 2.46 billion.
Performance metrics highlighted a strong earnings beat with adjusted EPS reaching USD 3.60, surpassing the consensus estimate of USD 2.94 by USD 0.66. This combination of higher revenue and superior profitability provides a solid foundation for Biogen's current valuation, supported by a market capitalization of USD 33.6 billion.
Analyst sentiment remains cautiously optimistic with a Moderate Buy consensus from 32 analysts, averaging a 12-month price target of USD 230.14. Management has outlined a clear strategic roadmap involving five registrational study readouts across key therapeutic areas including SLE, CLE, AMR, and Dravet syndrome over the coming quarters.
The company is scheduled to report third-quarter 2026 financial results before the market opens on October 28, 2026. Investors will be closely monitoring this upcoming checkpoint for continued revenue momentum, new product launches, and further progress in its clinical pipeline.
